Quintiles Works with NFL to Track Injuries and Understand Trends
10 Febrero 2015 - 7:00AM
Business Wire
Quintiles, the world’s largest biopharmaceutical services
company, is working with the National Football League (NFL) to
track player injuries and understand trends in injury
occurrence.
Quintiles, the world's largest
biopharmaceutical services company, is working with the National
Football League (NFL) to track player injuries and understand
trends in injury occurrence. (Photo: Business Wire)
Quintiles and the NFL have been working together since 2011,
when the Quintiles epidemiology group was tasked with designing a
new application that would modernize the league’s existing
Injury Surveillance System (ISS). The NFL recently signed a
five-year agreement with Quintiles to continue and expand upon its
Injury Surveillance and Analytics (ISA) service as it is now
known.
Quintiles records injury occurrence during pre-season training,
and continues throughout the regular season and playoffs. For the
2014-15 season, Quintiles began conducting injury surveillance
using the NFL’s newly implemented league-wide electronic medical
record (EMR) system, enhancing the ability to understand the
setting and impact of injuries. The ISA surveillance data are
maintained in a manner which protects player identities, consistent
with how Quintiles safeguards all confidential patient
information.
Quintiles has adapted its expertise in epidemiological methods
to provide insights about a variety of risk factors for sports
injuries including issues relating to rules, equipment and types of
surface. The analytics are conducted in response to questions posed
by the NFL, its teams, health and safety committees, physicians,
athletic trainers, players and the NFL Players Association (NFLPA)
and is shared with those groups in a series of reports and
face-to-face meetings over the football season.
“This partnership presents a unique opportunity for Quintiles to
leverage our epidemiological and real-world research expertise,”
said Nancy Dreyer, senior vice president and global head of
scientific affairs at Quintiles. “Through our innovative and rapid
analytic approach, Quintiles connects insights with superior
delivery for better outcomes, providing objective analysis in a
timely manner.”
“Conducting analytics using EMRs and other game-related
information substantially broadens our understanding of player
health and safety,” said Christina Mack, Quintiles associate
director of epidemiology. “Applying epidemiologic methods to these
data provides a more complete picture of changes in injury
occurrence over time.”
The NFL Injury Surveillance and Analytic service originates with
Quintiles’ Real-World & Late Phase Research business unit. As
part of its observational research and patient registry services,
this group provides programs for characterizing diseases,
evaluating safety and effectiveness of medical interventions,
understanding and improving patient outcomes, and implementing risk
management programs, in addition to sports injury research. The
research conducted by Real-World & Late Phase adds important
real-world evidence to knowledge about risk factors for disease
occurrence as well as the real-world risks and benefits of medical
interventions.
About Quintiles
Quintiles (NYSE: Q), a Fortune 500 company, is the world’s
largest provider of biopharmaceutical development and commercial
outsourcing services. With a network of more than 32,000 employees
conducting business in approximately 100 countries, we helped
develop or commercialize all of 2013’s top-100 best-selling drugs
on the market. Quintiles applies the breadth and depth of our
service offerings along with extensive therapeutic, scientific and
analytics expertise to help our customers navigate an increasingly
complex healthcare environment as they seek to improve efficiency
and effectiveness in the delivery of better healthcare outcomes. To
learn more about Quintiles, please visit www.quintiles.com.
Click here to subscribe to Mobile Alerts for Quintiles.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20150210005266/en/
QuintilesPhil Bridges, Media Relations
(phil.bridges@quintiles.com)919-998-1653 (office) 919-457-6347
(mobile)orKarl Deonanan, Investor Relations
(InvestorRelations@quintiles.com)919-998-2789
Qimonda AG Ads (NYSE:QI)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Qimonda AG Ads (NYSE:QI)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024